newsfilter
← Latest News
Business Wire·

Dicerna Initiates Phase 1 Clinical Trial of DCR-AUD, a Novel Investigational GalXC™ RNAi Therapeutic Candidate for the Treatment of Alcohol Use Disorder

– Trial to Evaluate Safety and Tolerability of DCR-AUD in Healthy Volunteers – – Trial Includes Ethanol Interaction Assessments to Evaluate Participants' Response to Alcohol After Receiving DCR-AUD – Dicerna Pharmaceuticals, Inc. (NASDAQ:D